We are proud to alert the readership of Journal of Clinical Oncology (JCO) to a recent series of publications in JCO Precision Oncology that describe novel statistical methods for precision oncology (https://ascopubs.org/po/collections/statistical-methods-precision-oncology).^1-14 Most articles focus on state-of-the-art methods in precision drug development in oncology but also include expert discussion on discovery, precision oncology care, and decision making. They cover the development and validation of risk models, the identification and validation of predictive markers, drug discovery, early phase dose determination, model-assisted designs, phase II biomarker-driven trials, phase III confirmatory trials, companion diagnostics, master protocols for basket trials and umbrella trials, subgroup analysis, selection of estimands for clinical trials, and clinical trials for rare tumors and pediatric cancer.

中文翻译：

---

精密肿瘤学中的统计方法。

我们很荣幸地提醒《临床肿瘤学杂志》（JCO）的读者注意JCO Precision Oncology上最近的一系列出版物，这些出版物描述了精确肿瘤学的新型统计方法（https://ascopubs.org/po/collections/statistical-methods-精密肿瘤学）。^1-14大多数文章关注肿瘤学中精确药物开发的最新方法，但也包括有关发现，精确肿瘤学护理和决策的专家讨论。它们涵盖了风险模型的开发和验证，预测标志物的识别和验证，药物发现，早期剂量确定，模型辅助设计，II期生物标志物驱动的试验，III期确认试验，伴随诊断，篮子的主要方案试验和总括试验，亚组分析，用于临床试验的估计量的选择以及罕见肿瘤和小儿癌症的临床试验。